Posted by Michael Wonder on 09 Apr 2022
Joint statement from CMS Administrator Chiquita Brooks-LaSure and FDA Commissioner Robert M. Califf on ensuring access to safe and effective treatments
8 April 2022 - Ensuring the availability of innovative interventions for people is a shared priority for both the CMS and the U.S. FDA.
We recognise the important and related – but different – roles of our respective agencies and know that CMS and FDA decisions have an outsized impact on the U.S. health care system, as well as implications for the rest of the world.
